A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults (The Harmony Study)

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 20 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

26 Feb 2024 Patient-centric Approach utility presented at the 2024 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
26 Feb 2024 Results assessing safety and efficacy of single and multiple food allergies with ADP101 presented at the 2024 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
22 Nov 2023 According to an Alladapt Immunotherapeutics media release, data from this study were presented at the 2023 American College of Allergy, Asthma, and Immunology Annual Meeting .

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com